Devin Malik, MD
Medical Oncology · Jackson, MINPI 1568722981
Payments from drug & device makers
Across 11 payments — averaging $258.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Daiichi Sankyo Inc.$2K
- Beigene USA, Inc.$125
- Sanofi-aventis U.S. LLC$100
- Amgen$27
- Beckman Coulter, Inc.$25
- E.r. Squibb & Sons, L.L.C.$18
- plus $53 from 4 others
What the payments were for
- Consulting fees$2,49888%
- Food & beverage$2188%
- Education$1295%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Daiichi Sankyo Inc. | 2 | $2,498 |
| Beigene USA, Inc. | 1 | $125 |
| Sanofi-aventis U.S. LLC | 1 | $100 |
| Amgen | 1 | $27 |
| Beckman Coulter, Inc. | 1 | $25 |
| E.r. Squibb & Sons, L.L.C. | 1 | $18 |
| Regeneron Healthcare Solutions, Inc. | 1 | $17 |
| Genentech USA, Inc. | 1 | $14 |
| Gilead | 1 | $12 |
| Sanofi | 1 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,844 in reported general payments places this provider in the 30th percentile of 170 medical oncology providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XtandiEnzalutamide | 19 | $240,140 |
| VerzenioAbemaciclib | 12 | $160,681 |
| KrazatiAdagrasib | 11 | $149,630 |
| VenclextaVenetoclax | 18 | $124,538 |
| InqoviDecitabine/Cedazuridine | 11 | $85,383 |
| EliquisApixaban | 68 | $50,012 |
| Abiraterone Acetate | 42 | $29,221 |
| XareltoRivaroxaban | 34 | $21,972 |
| Voriconazole | 14 | $3,351 |
| Exemestane | 12 | $1,869 |
| Hydroxyurea | 18 | $702 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 14 | $688 |
| Anastrozole | 39 | $559 |
| Dexamethasone | 31 | $386 |
| Acyclovir | 37 | $328 |
Paid to pharmacies, not to this prescriber.
Other medical oncology in Jackson
- Patricia Lo RussoDetroit$24.6M
- Manish SharmaGrand Rapids$19M
- Moshe TalpazAnn Arbor$13.7M
- Shirish GadgeelDetroit$11M
- Zachery ReichertAnn Arbor$10.6M
- Ammar SukariDetroit$8.4M
- Paul SwiecickiAnn Arbor$7.6M
- Rashmi ChughAnn Arbor$7M
- John KraussAnn Arbor$6.2M
- Emerson LimGrand Rapids$6.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.